Form 4: Artiva Biotherapeutics CFO Neha Krishnamohan Reports Acquisition of 50,000 Shares

Neha Krishnamohan, CFO of Artiva Biotherapeutics, reports the acquisition of 50,000 shares of common stock on September 12, 2024, as part of a restricted stock unit award.

Summary

• On September 12, 2024, Neha Krishnamohan, the Chief Financial Officer of Artiva Biotherapeutics, acquired 50,000 shares of common stock.
• The acquisition was a result of a restricted stock unit (RSU) award granted under the Issuer's 2024 Equity Incentive Plan.
• The price per share for the acquisition was $0.
• Following the transaction, Neha Krishnamohan beneficially owns 50,000 shares of Artiva Biotherapeutics common stock.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine disclosure of stock acquisition by an executive, which doesn't inherently indicate positive or negative news.

Positives

• The acquisition of shares by the CFO could be seen as a positive signal, indicating confidence in the company's future prospects.

Industry Context

Form 4 filings are standard practice and provide transparency into the transactions of company insiders, allowing investors to track ownership changes and potential alignment of interests.

Stakeholder Impact

• The acquisition of shares by the CFO may positively influence shareholder sentiment, reflecting confidence in the company's performance.

Key Dates